Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Taris Biomedical brings in $12.5mm through its Series C venture round

Executive Summary

Taris Biomedical Inc. (bladder disease treatments) has raised $12.5mm through what is believed to be its Series C venture round. Current shareholders Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures participated. The company will use the money to continue developing LiRIS (Lidocaine Releasing Intravesical System) for interstitial cystitis patients. Concurrent with the financing, Taris announced that it had dosed its first patient with LiRIS in a second Phase II study. The company has raised almost $50mm since its 2009 inception.
Deal Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register